SEARCH

SEARCH BY CITATION

References

  • 1
    Khan HN, Wyld L, Dunne B et al. Spindle cell carcinoma of the breast: a case series of a rare histological subtype. Eur. J. Surg. Oncol. 2003; 29; 600603.
  • 2
    Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am. J. Surg. 2006; 191; 657664.
  • 3
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989; 64; 14901499.
  • 4
    Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J. Pathol. 2004; 204; 131139.
  • 5
    Kung FYL, Tse GMK, Lo KW, Law BKB, Chang AR, Chen MH. Metachronous bilateral mammary metaplastic and infiltrating duct carcinomas: a molecular study for clonality. Hum. Pathol. 2002; 33; 677679.
  • 6
    Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer 1999; 85; 21702182.
  • 7
    Sneige N, Yaziji H, Mandavilli SR et al. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am. J. Surg. Pathol. 2001; 25; 10091016.
  • 8
    Denley H, Pinder SE, Tan PH et al. Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. Histopathology 2000; 36; 203209.
  • 9
    Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL. Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. Mod. Pathol. 2003; 16; 893901.
  • 10
    Dunne B, Lee AHS, Pinder SE, Bell JA, Ellis IO. An Immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum. Pathol. 2003; 34; 10091015.
  • 11
    Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am. J. Surg. Pathol. 2005; 29; 347353.
  • 12
    Carter MR, Hornick JL, Lester S, Fletcher CDM. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am. J. Surg. Pathol. 2006; 30; 300309.
  • 13
    Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49; 1021.
  • 14
    Lee AHS. The histological diagnosis of metastases to the breast from extramammary malignancies. J. Clin. Pathol. 2007; (in press).
  • 15
    Khanafshar E, Phillipson J, Schammel DP, Minobe L, Cymerman J, Weidner N. Inflammatory myofibroblastic tumor of the breast. Ann. Diagn. Pathol. 2005; 9; 123129.
  • 16
    Fletcher CDM. Soft tissue tumors. In FletcherCDM ed. Diagnostic histopathology of tumors, 3rd Edition. Edinburgh: Churchill Livingstone, 2007; 15271592.
  • 17
    Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am. J. Surg. Pathol. 2004; 28; 15061512.
  • 18
    Leibl S, Moinfar F. Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. Am. J. Surg. Pathol. 2006; 30; 450456.
  • 19
    Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443; 122132.
  • 20
    Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum. Pathol. 1989; 20; 732740.
  • 21
    Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J. Clin. Pathol. 2005; 58; 700704.
  • 22
    Tse GM, Tan PH, Putti TC, Lui PCW, Chaiwun B, Law BKB. Metaplastic carcinoma of the breast: a clinicopathological review. J. Clin. Pathol. 2006; 59; 10791083.
  • 23
    Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006; 208; 495506.
  • 24
    Christensen L, Schiodt T, Blichert-Toft M. Sarcomatoid tumours of the breast in Denmark from 1977 to 1987. A clinicopathological and immunohistochemical study of 100 cases. Eur. J. Cancer 1993; 29A; 18241831.
  • 25
    Moore T, Lee AHS. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. Histopathology 2001; 38; 6267.
  • 26
    Damera A, Evans AJ, Cornford EJ et al. Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br. J. Cancer 2003; 89; 13101313.
  • 27
    Wargotz ES, Norris HJ, Austin RM, Enzinger FM. Fibromatosis of the breast. A clinical and pathological study of 28 cases. Am. J. Surg. Pathol. 1987; 11; 3845.
  • 28
    Rosen PP, Ernsberger D. Mammary fibromatosis. A benign spindle-cell tumor with significant risk for local recurrence. Cancer 1989; 63; 13631369.
  • 29
    Devouassoux-Shisheboran M, Schammel MD, Man YG, Tavassoli FA. Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. Arch. Pathol. Lab. Med. 2000; 124; 276280.
  • 30
    Abraham SC, Reynolds C, Lee JH et al. Fibromatosis of the breast and mutations involving the APC/β-catenin pathway. (Erratum in: Hum Pathol 2002; 33; 379.). Hum. Pathol. 2002; 33; 3946.
  • 31
    Sawyer EJ, Hanby AM, Rowan AJ et al. The Wnt pathway, epithelial–stromal interactions, and malignant progression in phyllodes tumours. J. Pathol. 2002; 196; 437444.
  • 32
    Sawyer EJ, Hanby AM, Poulsom R et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J. Pathol. 2003; 200; 627632.
  • 33
    Foxcroft LM, Evans EB, Porter AJ. Difficulties in the pre-operative diagnosis of phyllodes tumours of the breast: a study of 84 cases. Breast 2007; 16; 2737.
  • 34
    Shimizu K, Masawa N, Yamada T, Okamoto K, Kanda K. Cytologic evaluation of phyllodes tumors as compared to fibroadenomas of the breast. Acta Cytol. 1994; 38; 891897.
  • 35
    Tse GMK, Ma TKF, Pang LM, Cheung H. Fine needle aspiration cytologic features of mammary phyllodes tumors. Acta Cytol. 2002; 46; 855863.
  • 36
    Komenaka IK, El-Tamer M, Pile-Spellman E, Hibshoosh H. Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch. Surg. 2003; 138; 987990.
  • 37
    Jacobs TW, Chen YY, Guinee DG et al. Fibroepithelial lesions with cellular stroma on breast core needle biopsy: are there predictors of outcome on surgical excision? Am. J. Clin. Pathol. 2005; 124; 342354.
  • 38
    Dillon MF, Quinn CM, McDermott EW, O’Doherty A, O’Higgins N, Hill ADK. Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery 2006; 140; 779784.
  • 39
    Lee AHS, Hodi Z, Ellis IO, Elston CW. Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology 2007; 51; 336344.
  • 40
    Kocova L, Skalova A, Fakan F, Rousarova M. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody. Pathol. Res. Pract. 1998; 194; 97104.
  • 41
    Umekita Y, Yoshida H. Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol. Int. 1999; 49; 807810.
  • 42
    Rajan PB, Cranor ML, Rosen PP. Cystosarcoma phyllodes in adolescent girls and young women: a study of 45 patients. Am. J. Surg. Pathol. 1998; 22; 6469.
  • 43
    Yilmaz E, Sal S, Lebe B. Differentiation of phyllodes tumors versus fibroadenomas. Mammographic and sonographic features. Acta Radiol. 2002; 43; 3439.
  • 44
    Chao TC, Lo YF, Chen SC, Chen MF. Sonographic features of phyllodes tumors of the breast. Ultrasound Obstet. Gynecol. 2002; 20; 6471.
  • 45
    Evans AJ, Wilson ARM, Blamey RW, Robertson JFR, Ellis IO, Elston CW. Phyllodes tumour. In Atlas of breast disease management: 50 illustrative cases. London: W B Saunders, 1998; 6970.
  • 46
    Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res. 1993; 53; 40714074.
  • 47
    Noguchi S, Yokouchi H, Aihara T et al. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 1995; 76; 17791785.
  • 48
    Kuijper A, Buerger H, Simon R et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J. Pathol. 2002; 197; 575581.
  • 49
    Sawyer EJ, Hanby AM, Ellis P et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am. J. Pathol. 2000; 156; 10931098.
  • 50
    Tse GMK, Lee CS, Kung FYL et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am. J. Clin. Pathol. 2002; 118; 522526.
  • 51
    Kracht J, Sapino A, Bussolati G. Malignant phyllodes tumor of breast with lung metastases mimicking the primary. Am. J. Surg. Pathol. 1998; 22; 12841290.
  • 52
    Lae M, Vincent-Salomon A, Savignoni A et al. Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod. Pathol. 2007; 20; 435444.
  • 53
    Jee KJ, Gong G, Ahn SH, Park JM, Knuutila S. Gain in 1q is a common abnormality in phyllodes tumours of the breast. Anal Cellular Pathol 2003; 25; 8993.
  • 54
    Tse GMK, Putti TC, Kung FYL et al. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod. Pathol. 2002; 15; 734740.
  • 55
    Tan PH, Jayabaskar T, Yip G et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod. Pathol. 2005; 18; 15271534.
  • 56
    Birch JM, Alston RD, McNally RJQ et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20; 46214628.
  • 57
    Sawyer EJ, Poulsom R, Hunt FT et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J. Pathol. 2003; 200; 5964.
  • 58
    Carvalho S, E Silva AO, Milanezi F et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J. Clin. Pathol. 2004; 57; 10751079.
  • 59
    Kersting C, Kuijper A, Schmidt H et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab. Invest. 2006; 86; 5461.
  • 60
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403410.
  • 61
    Moffat CJC, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology 1995; 27; 205218.
  • 62
    De Roos WK, Kaye P, Dent DM. Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br. J. Surg. 1999; 86; 396399.
  • 63
    Chen WH, Cheng SP, Tzen CY et al. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J. Surg. Oncol. 2005; 91; 185194.
  • 64
    Tan PH, Jayabaskar T, Chuah KL et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am. J. Clin. Pathol. 2005; 123; 529540.
  • 65
    Ben Hassouna J, Damak T, Gamoudi A et al. Phyllodes tumors of the breast: a case series of 106 patients. Am. J. Surg. 2006; 192; 141147.
  • 66
    Chaney AW, Pollack A, McNeese MD et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89; 15021511.
  • 67
    Reinfuss M, Mitu J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996; 77; 910916.
  • 68
    Barth RJ. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res. Treat. 1999; 57; 291295.
  • 69
    Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GPH. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur. J. Surg. Oncol. 2001; 27; 723730.
  • 70
    Zurrida S, Bartoli C, Galimberti V et al. Which therapy for unexpected phyllode tumour of the breast? Eur. J. Cancer 1992; 28; 654657.
  • 71
    Parker SJ, Harries SA. Phyllodes tumours. Postgrad. Med. J. 2001; 77; 428435.
  • 72
    Reinfuss M, Mitu J, Smolak K, Stelmach A. Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases. Eur. J. Cancer 1993; 29A; 12521256.
  • 73
    Asoglu O, Ugurlu MM, Blanchard K et al. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann. Surg. Oncol. 2004; 11; 10111017.
  • 74
    Powell CM, Rosen PP. Adipose differentiation in cystosarcoma phyllodes: a study of 14 cases. Am. J. Surg. Pathol. 1994; 18; 720727.
  • 75
    Burga AM, Tavassoli FA. Periductal stromal tumor: a rare lesion with low-grade sarcomatous behavior. Am. J. Surg. Pathol. 2003; 27; 343348.